Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
January 31, 2019updated 07 Aug 2019 2:34pm

Genentech to suspend CREAD trials of Alzheimer’s disease drug

Genentech has decided to suspend the CREAD 1 and CREAD 2 trials designed to study crenezumab in patients with early (prodromal to mild) sporadic Alzheimer’s disease (AD).

Genentech has decided to suspend the CREAD 1 and CREAD 2 trials designed to study crenezumab in patients with early (prodromal to mild) sporadic Alzheimer’s disease (AD).

The decision is the result of data gained from a pre-planned interim analysis carried out by an Independent Data Monitoring Committee on the safety and efficacy of crenezumab.

The evaluation showed that crenezumab is unlikely to meet the trials’ primary endpoint of change from baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score.

“While the results with crenezumab are disappointing, they meaningfully contribute to our understanding of Alzheimer’s disease.”

No safety signals of crenezumab were found in the evaluation, which observed consistent overall safety profile of the drug with those revealed in previous trials.

Genentech Global Product Development head and chief medical officer Sandra Horning said: “While the results with crenezumab are disappointing, they meaningfully contribute to our understanding of Alzheimer’s disease.

“We remain dedicated to the Alzheimer’s community and will continue our Phase III GRADUATE trials with gantenerumab and the Phase II TAURIEL trial with the anti-tau molecule RG6100, as well as our imaging and fluid-based diagnostic solutions.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The CREAD 1 and 2 trials are Phase III, two-year global, randomised, double-blind, placebo-controlled, parallel-group studies. They are designed to test the efficacy and safety of crenezumab in 1,500 people worldwide with early AD with confirmed evidence of cerebral beta amyloid pathology (CSF or amyloid PET).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU